Peer-reviewed veterinary case report
New oral drug combo tested for mouth cancer in cats
By Skorupski, K A et al.·Published in Veterinary and comparative oncology·2011·Department of Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.
- Species:
- cat
Plain-English summary
A group of 13 cats with oral squamous cell carcinoma (a type of mouth cancer) were treated with two medications, DFMO and MQT 1426, to see if they could reduce tumor growth. While some cats experienced side effects like balance issues, these were temporary and went away after treatment. The therapy successfully lowered certain harmful substances in the tumors, and two cats showed signs of tumor shrinkage while six others had stable disease. This suggests that this treatment could be a promising option for cats with this type of cancer.
People also search for: cat mouth cancer treatment · feline squamous cell carcinoma symptoms · DFMO for cats cancer
Abstract
Polyamines are essential for cell proliferation. Their production is dysregulated in many cancers and polyamine depletion leads to tumour regression in mouse models of squamous cell carcinoma (SCC). The purpose of this study was to determine the maximally tolerated dose of the polyamine transport inhibitor, MQT 1426, when combined with the ornithine decarboxylase (ODC) inhibitor, DFMO, and to determine whether this therapy results in reduction in tumour polyamine levels. Thirteen cats with oral SCC received both drugs orally and serial tumour biopsies were obtained for polyamine measurement. Cats were monitored for response to therapy and toxicity. A maximum tolerated dose (MTD) of MQT 1426 when combined with DFMO was determined. Dose-limiting toxicity was vestibular in nature, but was fully reversible. Spermidine and total polyamine levels decreased significantly in tissues, two cats experienced objective tumour regression and six cats had stable disease. These results suggest that further study of polyamine depletion therapies is warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22077408/